Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Immuneering (IMRX) over the last 5 years, with Dec 2024 value amounting to $355,807.

  • Immuneering's Depreciation & Amortization (CF) fell 4.05% to $86,116 in Q4 2024 from the same period last year, while for Dec 2024 it was $355,807, marking a year-over-year increase of 10.22%. This contributed to the annual value of $355,807 for FY2024, which is 10.22% up from last year.
  • According to the latest figures from FY2024, Immuneering's Depreciation & Amortization (CF) is $355,807, which was up 10.22% from $322,816 recorded in FY2023.
  • In the past 5 years, Immuneering's Depreciation & Amortization (CF) registered a high of $355,807 during FY2024, and its lowest value of $24,328 during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $308,607, with a median of $322,816 in 2023.
  • Data for Immuneering's Depreciation & Amortization (CF) shows a peak YoY soared of 443.69% (in 2022) over the last 5 years.
  • Immuneering's Depreciation & Amortization (CF) (Yearly) stood at $24,328 in 2020, then soared by 86.89% to $45,467 in 2021, then soared by 443.69% to $247,199 in 2022, then skyrocketed by 30.59% to $322,816 in 2023, then increased by 10.22% to $355,807 in 2024.